PurposeTo analyze the optimum organ filling point for organs at risk (OARs) dose in cervical cancer high-dose-rate (HDR) brachytherapy.Material and methodsIn a retrospective study, 32 locally advanced cervical cancer patients (97 insertions) who were treated with 3D conformal external beam radiation therapy (EBRT) and concurrent chemotherapy during 2010-2013 were included. Rotterdam HDR tandem-ovoid applicators were used and computed tomography (CT) scanning was performed after each insertion. The OARs delineation and GEC-ESTRO-based clinical target volumes (CTVs) contouring was followed by 3D forward planning. Then, dose volume histogram (DVH) parameters of organs were recorded and patients were classified based on their OARs volumes, as well as their inserted tandem length.ResultsThe absorbed dose to point A ranged between 6.5-7.5 Gy. D0.1cm3 and D2cm3 of the bladder significantly increased with the bladder volume enlargement (p value < 0.05). By increasing the bladder volume up to about 140 cm3, the rectum dose was also increased. For the cases with bladder volumes higher than 140 cm3, the rectum dose decreased. For bladder volumes lower than 75 cm3, the sigmoid dose decreased; however, for bladder volumes higher than 75 cm3, the sigmoid dose increased. The D2cm3 of the bladder and rectum were higher for longer tandems than for shorter ones, respectively. The divergence of the obtained results for different tandem lengths became wider by the extension of the bladder volume. The rectum and sigmoid volume had a direct impact on increasing their D0.1cm3 and D2cm3, as well as decreasing their D10, D30, and D50.ConclusionsThere is a relationship between the volumes of OARs and their received doses. Selecting a bladder with a volume of about 70 cm3 or less proved to be better with regards to the dose to the bladder, rectum, and sigmoid.

Small‐animal single‐photon emission computed tomography (SPECT) system plays an important role in the field of drug development and investigation of potential drugs in the preclinical phase. The small‐animal High‐Resolution SPECT (HiReSPECT) scanner has been recently designed and developed based on compact and high‐resolution detectors. The detectors are based on a high‐resolution parallel hole collimator, a cesium iodide (sodium‐activated) pixelated crystal array and two H8500 position‐sensitive photomultiplier tubes. In this system, a full set of data corrections such as energy, linearity, and uniformity, together with resolution recovery option in reconstruction algorithms, are available. In this study, we assessed the performance of the system based on NEMA‐NU1–2007 standards for pixelated detector cameras. Characterization of the HiReSPECT was performed by measurement of the physical parameters including planar and tomographic performance. The planar performance of the system was characterized with flood‐field phantom for energy resolution and uniformity. Spatial resolution and sensitivity were evaluated as functions of distance with capillary tube and cylindrical source, respectively. Tomographic spatial resolution was characterized as a function of radius of rotation (ROR). A dedicated hot rod phantom and image quality phantom was used for the evaluation of overall tomographic quality of the HiReSPECT. The results showed that the planar spatial resolution was ~1.6.15emmm and ~.15em2.3.15emmm in terms of full‐width at half‐maximum (FWHM) along short‐ and long‐axis dimensions, respectively, when the source was placed on the detector surface. The integral uniformity of the system after uniformity correction was 1.7% and 1.2% in useful field of view (UFOV) and central field of view (CFOV), respectively. System sensitivity on the collimator surface was 1.31.15emcps/μCi and didn't vary significantly with distance. Mean tomographic spatial resolution was measured ∼1.7 mm FWHM at the radius of rotation of 25 mm with dual‐head configuration.The measured performance demonstrated that the HiReSPECT scanner has acceptable image quality and, hence, is well suited for preclinical molecular imaging research.PACS number: 87.57.U

No abstract

The purpose of this study was to investigate the concurrent effects of tandem length and bladder volume on dose to pelvic organs at risk (OARs) in HDR intracavitary brachytherapy treatment of cervical cancer. Twenty patients with locally advanced cervical cancer were selected for brachytherapy using Rotterdam applicators. The patients were CT scanned twice with empty and full bladder. Two treatment plans were prepared on each of the image sets. Patients were categorized into two groups; those treated with a tandem length of 4 cm or smaller false(T≤4 cmfalse) and those with tandem length larger than 4 cm (T>4 cm). Only one tandem tip angle of 30° was studied. Dose‐volume histograms (DVHs) of OARs were calculated and compared. Bladder dose was significantly affected by both bladder volume and tandem physical length for T≤4 cm. This was reflected on the values obtained for normalD2cm3, normalD1cm3, and normalD0.1cm3 for both empty and full bladder cases. When T>4 cm, no correlation could be established between variations in bladder dose and bladder volume. Rectum dose was generally lower when the bladder was empty and T>4 cm. Dose to sigmoid was increased when T>4 cm; this increase was larger when the bladder was full. Our results suggest that, for tandems longer than 4 cm, keeping the bladder empty may reduce the dose to rectum and sigmoid. This is contrary to cases where a shorter than 4 cm tandem is used in which a full bladder (about 50–120 cm3) tends to result in a lower dose to rectum and sigmoid. Attention should be given to doses to sigmoid with long tandem lengths, as a larger tandem generally results in a larger dose to sigmoid.PACS number(s): 87.53.Jw

BackgroundMarketing new radiography devices necessitates documenting their absorbed X-ray doses. Since the current literature lacks studies on new devices, we assessed the doses of two new devices that had not previously been assessed.ObjectivesThe new devices were compared to the Promax three dimensional (3D) scanner at two fields of view (FOV) in nine critical head and neck tissues and organs.Materials and MethodsSeventeen thermoluminescence dosimeters positioned in an average-sized male RANDO phantom were used to determine the dosimetry of the three cone beam computerized tomography devices (NewTom VGi, NewTom 5G, and Promax 3D) at two field of views (FOVs), one small and one large. The exposure by each device per FOV was performed five times (30 exposures). The absorbed and effective doses were calculated for the thyroid, parotid, submandibular gland, sublingual gland, calvarium, cervical vertebra, trunk of the mandible, and mandibular ramus. The doses pertaining to the different devices, the FOVs, and the tissues were compared using the Kruskal-Wallis, Mann-Whitney U, and Wilcoxon tests.ResultsThe average absorbed doses, respectively, for the large and small FOVs were 17.19 and 28.89 mGy in the Promax 3D, 19.25 and 35.46 mGy in the NewTom VGi, and 18.85 and 30.63 mGy in the NewTom 5G. The absorbed doses related to the FOVs were not significantly different (P value = 0.1930). However, the effective doses were significantly greater at the smaller FOVs / higher resolutions (P = 0.0039). The doses of the three devices were not significantly different (P = 0.8944). The difference among the nine organs/tissues was significant (Kruskal-Wallis P=0.0000).ConclusionThe absorbed doses pertaining to the devices and the FOVs were not significantly different, although the organs/tissues absorbed considerably different doses.